Elbasvir/Grazoprevir
- Generic Name
- Elbasvir/Grazoprevir
Drug-Drug Interactions of Grazoprevir/Elbasvir in Taiwan
- First Posted Date
- 2018-10-15
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- National Cheng-Kung University Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT03706222
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk
- First Posted Date
- 2018-07-12
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- University of California, Los Angeles
- Registration Number
- NCT03585101
- Locations
- 🇺🇸
UCLA CARE Center, Los Angeles, California, United States
Grazoprevir and Elbasvir Without Ribavirin for 12 Weeks in Patients With HCV-related Cryoglobulinemic Nephropathy
- Conditions
- Cryoglobulinaemic GlomerulonephritisHepatitis C
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2018-02-14
- Lead Sponsor
- University of Florence
- Target Recruit Count
- 45
- Registration Number
- NCT03433326
A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A
- First Posted Date
- 2017-04-07
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- Fundacion SEIMC-GESIDA
- Registration Number
- NCT03105349
- Locations
- 🇪🇸
Hospital Infanta Leonor, Madrid, Spain
🇪🇸Hospital Univ. Gregorio Marañon, Madrid, Spain
🇪🇸Hospital Univ. La Paz, Madrid, Spain
Pembrolizumab With or Without Elbasvir/Grazoprevir and Ribavirin in Treating Patients With Advanced Refractory Liver Cancer
Phase 2
Completed
- Conditions
- BCLC Stage B Hepatocellular CarcinomaStage IV Hepatocellular Carcinoma AJCC v7Stage IVA Hepatocellular Carcinoma AJCC v7BCLC Stage C Hepatocellular CarcinomaStage III Hepatocellular Carcinoma AJCC v7Stage IIIB Hepatocellular Carcinoma AJCC v7Refractory Liver CarcinomaStage IVB Hepatocellular Carcinoma AJCC v7Hepatitis C InfectionStage IIIA Hepatocellular Carcinoma AJCC v7
- Interventions
- Other: Laboratory Biomarker AnalysisBiological: Pembrolizumab
- First Posted Date
- 2016-10-21
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 12
- Registration Number
- NCT02940496
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath